Patent landscape of small molecule inhibitors of METTL3 (2020-present)

Introduction Methyltransferase-like protein 3 (METTL3), in complex with METTL14, is the key 'writer' protein for RNA m6A methylation, accounting for almost all mRNA m6A modifications. Recent studies reveal that METTL3 is implicated in the development and progression of various types of cancers. Targeting METTL3 with small molecule inhibitors represents a promising therapeutic strategy for cancer.